VISTECH grant for Anadis
Tuesday, 01 July, 2008
Melbourne's Anadis (ASX: ANX) has been awarded a significant grant from VISTECH for its alimentary mucositis treatment.
The grant is one of only three awarded from VISTECH, a bi-national fund granted by the Victorian and the Israeli Governments, and was awarded through a competitive process including a vigorous scientific assessment.
The US$500,000 grant was awarded to Anadis and its Israeli collaborator Maya BioTech. The money will be used to help fund a clinical trial of polyclonal antibodies, which is expected to take between 18-24 months.
Anadis is predicting to be able to launch a commercial product in as little as two years.
Gastro-intestinal and oral mucositis is a significant side effect of cancer therapy.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
